Delhi based women’s hygiene brand Pee Safe has successfully raised $32 million in its Series C funding round from global healthcare focused private equity firm OrbiMed. The investment combines fresh primary capital with secondary share sales, building on previous funding of approximately $22 million from investors including Zerodha co founder Nikhil Kamath, Eight Roads Ventures, and 3one4 Capital.
The newly acquired funds will drive expansion across multiple channels. Pee Safe plans to substantially broaden its brick and mortar retail network, amplify brand led marketing campaigns, and accelerate presence on quick commerce platforms and digital marketplaces. OrbiMed’s Dr. Sunny Sharma and Sumona Chakraborty have joined the company’s board, bringing valuable healthcare industry expertise beyond capital investment.
From Single Product to Multi-Category Wellness Portfolio
Founded in 2013 by Vikas and Srijana Bagaria, Pee Safe began with a toilet seat sanitizer spray addressing urinary tract infection concerns in public restrooms. Rithish Kumar, who joined as cofounder in 2017 and received official recognition in 2023, has been instrumental in transforming the venture into a comprehensive personal care brand with over 25 products.
Today’s portfolio spans organic cotton tampons, menstrual cups, intimate wash products for both genders, maternity care items, and anti-pollution masks. In March 2020, the company launched Raho Safe, an affordable sub brand targeting tier 3 and 4 cities to promote menstrual hygiene awareness and combat period poverty through accessible sanitary pads and hygiene products.
Strong Market Position on Path to Profitability
Pee Safe’s operational footprint demonstrates significant market penetration. The brand reaches consumers through approximately 40,000 retail outlets across more than 100 Indian cities, complemented by strong presence on Amazon, Nykaa, and Flipkart. International expansion extends to 23 countries, serving over six million customers globally.
Financial performance reveals promising momentum. The company achieved Rs 82 crore in revenue during FY25 while dramatically reducing losses by 70 percent to Rs 4 crore from Rs 13 crore in FY24. This improvement reflects a sustained 100 percent CAGR over five years, positioning Pee Safe on a clear trajectory toward profitability.
Operating in India’s rapidly growing femtech segment with 16 percent CAGR, Pee Safe competes against specialized brands like Sirona and Sanfe alongside giants Johnson & Johnson and Procter & Gamble. With institutional backing from OrbiMed and proven market traction, the company is well-positioned to capture greater market share while continuing its mission to eliminate taboos surrounding women’s health and hygiene.
Also Read: Sukino Healthcare Secures $31 Million Series B Funding Led by Bessemer Venture Partners
